On June 17, 2020, Gibson Diagnostic Labs made the following statement:

In April 2020, a commercial insurer doing business with Gibson Diagnostic Labs inquired about the Company’s pricing practices regarding COVID-19 testing. In response to the inquiry, the Company conducted an internal review and identified commercial claims that were billed incorrectly by the Company’s third-party biller. Because this incident did not meet our standards of quality, service and compliance, the Company terminated its relationship with the third-party biller. A few of the claims at issue resulted in an overpayment, which the Company has returned to the commercial payors. Gibson Diagnostic Labs takes this matter very seriously. We have implemented a series of corrective actions to prevent this issue from happening again. At no time were federal payors affected and the Company received no taxpayer dollars.

We apologize to our clients, patients and employees for any disruption or inconvenience that occurred.